Mergers & Acquisitions

"[T]he knowledge and depth of the practice's bench for multi-faceted transactions is superb." - Legal 500

In recent years, Cadwalader has emerged as a leading mergers and acquisitions firm, with a nationally recognized team of attorneys that has been called on to handle some of the largest and most complex deals in the marketplace. 

Providing assistance beginning at the earliest stages of a transaction, Cadwalader attorneys advise clients—buyers, sellers and financial advisors—in evaluating and developing alternative strategies for achieving business objectives, structuring and documenting deals, arranging financing, and obtaining regulatory approvals. We are known for our ability to structure and coordinate creative and complex transaction structures with long-term tax benefits, operating efficiencies, and enhanced rate of return and for our expertise in the areas of law that frequently affect mergers and acquisitions, such as antitrust; environmental; employee benefits; insolvency; tax; litigation; and securitization. In addition, we are proficient at coordinating and guiding other professionals, such as investment bankers, accountants, and actuaries, to complete transactions efficiently and effectively. 

  • Salix Pharmaceuticals, Ltd. in its pending $14.5 billion acquisition by Valeant Pharmaceuticals International, Inc.
  • Acorda Therapeutics, Inc. in its acquisition of Civitas Therapeutics, Inc.
  • Forbes Media LLC on its pending sale of a majority stake to a group of international investors as part of the Company's global growth strategy.
  • Salix Pharmaceuticals in its terminated combination with Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals, to form Salix Pharmaceuticals, plc.
  • Air Products and Chemicals in its agreement with Pershing Square Capital Management following the 9.8% investment position taken by Bill Ackman.
  • Dell Inc.’s financial advisor in connection with Dell’s $24.9 billion acquisition by Michael Dell and Silver Lake Partners.
  • Elan Corporation in its $8.6 billion acquisition by Perrigo Company.
  • Elan Corporation in its successful defense of a hostile tender offer by Royalty Pharma.
  • Elan Corporation in its plan to spin-off discovery science and Neotope Biosciences to shareholders.
  • AngioDynamics, manufacturer of minimally invasive medical devices for vascular access, surgery, peripheral vascular disease, and oncology practices, in its acquisition of Navilyst Medical in a $372 million transaction.
  • Towers Watson & Co. in its $435 million acquisition of Extend Health Inc.
  • DPL Inc. in its $4.7 billion sale to AES Corp.
  • U.S. Treasury Department in the sale of its remaining equity interests in Chrysler Group LLC to Fiat S.p.A, marking the end of the U.S. government's ownership stake in Chrysler.
  • Pfizer Inc. in the $2.38 billion sale of its Capsugel unit to private equity group Kohlberg Kravis Roberts & Co.
  • The Renco Group's $1.2 billion stock purchase of three steel companies from Russian-based OAO Severstal through its wholly-owned subsidiary RG Steel.
  • Societe Generale in connection with acquisition of an equity interest of J.C. Penney by Pershing Square and Vornado Realty.
  • Procter & Gamble in its $2.35 billion sale of the Pringles brand to Diamond Foods.
  • Pfizer Inc.'s acquisition of King Pharmaceuticals, Inc.
  • Pfizer Inc.'s acquisition of Wyeth.
  • CVC Capital Partners Group in its proposed acquisition of Barclays' iShares unit, a leading global provider of exchange traded funds.
  • Bear Stearns acquisition by JP Morgan Chase.
  • Pfizer Inc.'s sale of its consumer healthcare business to Johnson & Johnson.
  • The Procter & Gamble Company's acquisition of The Gillette Company.
  • Pfizer Inc.'s acquisition of Pharmacia.
  • Pfizer Inc.'s acquisition of Warner-Lambert.
  • The sale of Quaker Oats to PepsiCo.
  • Pfizer Inc.'s sale of Schick-Wilkinson to Energizer.
  • Pfizer Inc.'s sale of its Adam's Confectionary division to Cadbury Schweppes.
  • The sale of Storage Tek to Sun Microsystems.
  • Pfizer Inc.'s acquisition of Vicuron Pharmaceuticals.



14 Attorneys

Alin, Andrew P. Partner New York
T. +1 212 504 6889
Bevilacqua, Louis J. Senior Counsel New York
T. +1 212 504 6057
Brand, Richard M. Partner New York
T. +1 212 504 5757
Cox, Christopher T. Senior Counsel New York
T. +1 212 504 6888
Fritts, John F. Senior Counsel New York
T. +1 212 504 6293
Gosby, Elin Associate London
T. +44 (0) 20 7170 8644
Halper, Jason M. Partner New York
T. +1 212 504 6300
McCurrach, Braden Special Counsel New York
T. +1 212 504 6788
Mills, William P. Partner New York
T. +1 212 504 6436
Patti,, Gregory P. Jr. Partner New York
T. +1 212 504 6780
Raglan, Daniel Special Counsel New York
T. +1 212 504 6790
Risell, Adam Z. Associate Washington
T. +1 202 862 2388
Saha, Sinjini Partner London
T. +44 (0) 20 7170 8534
Wei, Edward S. Partner New York
T. +1 212 504 6799


Richard M. Brand
+1 212 504 5757
William P. Mills
+1 212 504 6436

Cadwalader News

ACI Summit on Controlled Substances: Regulation, Litigation and Enforcement

Jodi Avergun is speaking at this ACI event on January 30 in Washington, DC.

Cadwalader Subscription Center